Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1997 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Pancho Villa who wrote (6541)	11/6/1997 8:54:00 AM
From: Hank	Respond to of 9285

Pancho, Like I said before, the liability will most likely rest upon the shoulders of Wyeth since they were probably in charge of getting the drug through the FDA. IPIC could simply declare bankruptcy after selling off it's assests to Intercardia and selling off it's other drug candidates to the big drug firms. Chances are, they would not be bought out lock, stock and barrel by any one company but bought out in pieces. That's what I was really driving at. Buying up portions of IPIC's business would not make the buyer liable for Redux. In the end, you would be right, IPIC would technically be out of business. As for hedging with a long postion in Intercardia, it was an off handed thought on my part. I have not looked into Intercardia closely enough to offer a firm opinion on the soundness of this approach but it's something to look into. Hank